Developing the next generation topical eczema treatment
Our Solution – Beneficial inflammatory modulation and reduction of itch
TIRmed Pharma’s immunomodulators selectively inhibits certain innate immune responses while leaving other parts of the immune system intact. The immunomodulators act early in the inflammatory cascade. The approach represents a novel method to modulate immune responses and ameliorate itch.
The Product – Topical anti-itch formulation
TIRmed Pharma’s product candidate is formulated in a cream aiming for a self-applied and easy to use at-home anti-itch treatment. The product is intended for mild to moderate symptoms before the need of biologicals. Topical delivery to the skin limits systemic adverse events. TIRmed’s product is a next generation topical treatment without steroids.
Board of Directors and Management
Ph.D. Chairman of the Board
Jan-Erik Nyström has more than 25 years experiences from leading industrial research positions including 21 years from AstraZeneca in roles such as director of medicinal chemistry, head of the Swedish discovery research organization in CNS and Pain Control therapeutic area, director of external collaborations. Co-founder of TIRmed Pharma AB.
M.D., Ph.D Board member, CEO
Anna-Lena Spetz is professor in immunology and leading a research group at the Department of Molecular Biosciences, The Wenner-Gren Institute (MBW) at Stockholm University. She has previous research experiences from Harvard Medical School and Karolinska Institutet. Her research interests are novel ways to treat immune responses and to relieve itch. She has previous experience as co-founder and board member in a small biotech company Avaris AB that was operating 2001-2012. Co-founder and CEO of TIRmed Pharma AB.
Ph.D representative owner SU Holding AB
Mona Wilcke has a broad experience in pharmaceutical development from big pharma as well as the biotech industry. She has a background in biochemistry and has also spent the last years in seed investments and start-ups. At present, she is the CEO of SU Holding AB, (Stockholm University Holding) that is one of the co-founders of TIRmed Pharma AB.
BSc Board member
Leo Holmgren has a business degree from Warwick Business School and is currently a Masters student at London Business School.
He has former start-up experiences and a financial expertise that complements the rest of the operational team.